Large-scale plasma proteomics uncovers preclinical molecular signatures of Parkinson's disease and overlap with other neurodegenerative disorders

Jan Homann[1], Alexander G. Smith[2,*], Sarah Morgan[3,*], Elisabet A. Frick[4,5*], Fangyu Liu[6,*], Vivian Viallon[7,*], Rashmi Maurya[8], Roxanna Korologou-Linden[9], Valerija Dobricic[10], Olena Ohlei[1], Laura Deecke[1], Fatema Hajizadah[3], Yujia Zhao[11], Fanny Artaud[12], Karl Smith-Byrne[13], P. Martijn Kolijn[11], Jose Maria Huerta[14,15], Nils Winter[16], Marcela Guevara[15,17,18], Ana Jimenez-Zabala[19,20], María José Sánchez[15,21,22], Camino Trobajo-Sanmartín[15,17,18], Natalia Cabrera-Castro[14,15], Ana Vinagre[19,23], Dafina Petrova[15,21,22,24], Sabina Sieri[25], Tim J. Key[13], Nick Wareham[26], Rudolph Kaaks[27], Ruth C. Travis[13], Tim Hahn[16], Susan Baker[9], Sean M. Kelly[28], Roel Vermeulen[11,29], Susan Peters[11], Giovanna Masala[30], Carlotta Sacerdote[31], Nancy Finkel[32], The Global Neurodegeneration Proteomics Consortium (GNPC)[$], Alexis Elbaz[12], Moritz Hess[33], Verena Katzke[26], Lars Bertram[10], Vilmundur Gudnason[4,5], Oliver Robinson[2,9], Honglei Chen[34], Lefkos Middleton[9], Laura M. Winchester[8], Ioanna Tzoulaki[2], Valborg Gudmundsdottir[4,5], Keenan A. Walker[35], Pietro Ferrari[7], Elio Riboli[2], Marc J. Gunter[2], Christina M. Lill[1,9,#]

Affiliations:
1. Institute of Epidemiology and Social Medicine, University of Münster, Münster, Germany
2. Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
3. Centre for Neuroscience, Surgery and Trauma, Blizard Institute, Queen Mary University of London, London, UK
4. Icelandic Heart Association, Kopavogur, Iceland
5. Faculty of Medicine, Department of Health Sciences, University of Iceland, Reykjavik, Iceland
6. Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA
7. International Agency for Research on Cancer (IARC/WHO), Nutrition and Metabolism Branch, Lyon, France
8. Department of Psychiatry, University of Oxford, Oxford, UK
9. Ageing and Epidemiology Unit (AGE), School of Public Health, Imperial College London, London, UK
10. Lübeck Interdisciplinary Platform for Genome Analytics (LIGA), University of Lübeck, Lübeck, Germany
11. Institute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands
12. Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, Villejuif, France
13. Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
14. Department of Epidemiology, Murcia Regional Health Council, Biomedical Research Institute of Murcia-IMIB, Murcia, Spain
15. Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
16. Institute of Translational Psychiatry, University of Münster, Münster, Germany
17. Instituto de Salud Pública y Laboral de Navarra, Pamplona, Spain
18. Navarre Institute for Health Research (IdiSNA), Pamplona, Spain
19. Biogipuzkoa Health Research Institute, San Sebastian, Gipuzkoa, Spain
20. Ministry of Health of the Basque Government, Sub-Directorate for Public Health and Addictions of Gipuzkoa, San Sebastián, Gipuzkoa, Spain
21. Escuela Andaluza de Salud Pública (EASP), Granada, Spain

22. Instituto de Investigación Biosanitaria ibs.GRANADA, Granada, Spain
23. Osakidetza Basque Health Service, Donostia University Hospital, Neurology Department, San Sebastián,
Gipuzkoa, Spain
24. Servicio de Oncología Médica. Hospital Universitario Virgen de las Nieves, Granada, Spain
25. Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano Via Venezian,
Milan, Italy
26. Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, UK
27. Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
28. NYU Langone Health Department of Neurology
29. University Medical Centre Utrecht, Utrecht, The Netherlands
30. Clinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO),
Florence, Italy
31. Department of Health Sciences, University of Eastern Piedmont, Novara, Italy
32. Novartis, Cambridge, MA, USA
33. Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center, University of Freiburg,
Germany
34. Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA
35. Laboratory of Behavioral Neuroscience, National Institute on Aging, Baltimore, Maryland, USA
*These authors contributed equally as shared second authors.
$For the index GNPC author list, see Supplementary Information.
64
#Corresponding Author:
Dr. Christina Lill, MD, MSc, Translational Epidemiology Unit, Institute of Epidemiology and Social Medicine,
University of Münster, Domagkstr. 3, 48149 Münster, Germany, telephone: +49 251 83 57101, email:
christina.lill@uni-muenster.de and clill@ic.ac.uk

ABSTRACT

Parkinson's disease (PD) remains incurable, with a long preclinical phase currently
undetectable by existing methods. In the largest proteomic study in neurodegenerative
diseases to date, we analyzed blood samples from ~74,000 individuals across discovery and
validation cohorts. In the EPIC4PD discovery case-cohort, large-scale profiling of 7,285
proteins (SomaScan-7K) in 4,538 initially unaffected participants (574 incident cases)
identified 17 proteins that predict PD up to 28 years before diagnosis. Additional proteins
revealed sex-specific effects and time-dependent effect trajectories, capturing disease
progression before symptom onset. Replication in three prospective cohorts (n=64,856;
1,034 incident cases) confirmed at least 12 key pre-diagnostic biomarkers with strong
evidence, including TPPP2, HPGDS, ALPL, MFAP5, OGFR, ACAD8, TCL1A, GPC4, GSTA3, LCN2,
KRAS, and GJA1. Preclinical biomarkers showed 86% concordant effect directions in
independent prevalent PD cases (n=2,592; p=1.6×10^{-19}). Furthermore, in the longitudinal
Tracking PD cohort (n=794), HPGDS and MFAP5 also predicted cognitive decline. Notably,
several of the identified PD biomarkers overlapped with those for incident Alzheimer's
disease and amyotrophic lateral sclerosis, indicating shared molecular signatures. A machine
learning-derived protein score improved PD risk prediction in external validation. This
extensive proteomics effort identified novel, actionable biomarkers opening new avenues
for early PD risk stratification and precision medicine.

Keywords: Parkinson's disease, neurodegeneration, prediction, proteomics, protein risk
score, SomaLogic, aptamers, EPIC

INTRODUCTION

Parkinson's disease (PD) is the most common movement disorder and the second most

common neurodegenerative disease after Alzheimer's disease (AD)[1]. It is characterized by

progressive, disabling motor and non-motor symptoms, substantially reducing quality of life

and life expectancy[2,3]. By the time PD is clinically diagnosed, significant neuronal loss has

already occurred, and available treatments are only symptomatic, with diminishing benefits

over time[1]. Consequently, the disease poses a significant burden not only on patients but

also on their families and caregivers. Furthermore, its prevalence is projected to rise sharply,

particularly in aging societies, leading to increasing financial and social costs[2].

Importantly, non-specific symptoms may begin up to 20 years before diagnosis, suggesting

that PD pathophysiology starts even earlier[4]. This time course points to a critical window for

preventive or early therapeutic interventions that could delay or halt disease onset.

However, identifying at-risk but clinically unaffected individuals remains a significant

challenge. Developing a reliable PD risk score — such as one based on molecular biomarkers

— will be essential to address this gap. Such a score would be especially valuable for risk

stratification in vulnerable populations, including workers in rural areas with pesticide

exposure or individuals with a family history of PD. By identifying those at highest risk,

targeted monitoring and the initiation of early clinical and preventive trials could be

implemented more effectively. In this context, high-throughput proteomic platforms such as

SomaScan® (SomaLogic, Inc.) and Olink® (Olink Proteomics AB) offer new exciting

opportunities to identify novel biological signatures of PD development. These methods can

quantify thousands of proteins simultaneously and hold strong potential for identifying

biomarkers that can detect diseases in their earliest or even preclinical stages[5–7]. In

neurodegenerative diseases interest in blood-based biomarkers has grown, owing to their

minimally invasive collection, easier clinical integration, and strong performance of

candidate blood biomarkers in AD[8]. In PD, such markers could enhance early diagnosis,

enable risk stratification in clinical trials, and support preventive strategies. However, given

PD's comparatively low prevalence (2-3% in individuals aged 65+)[1], prospective cohorts with

long-term follow-up are rare. Even more rare are cohorts with baseline blood samples —

collected before PD onset — which are required to identify predictive biomarkers. This is

why most prior biomarker studies have compared prevalent PD patients to controls, risking

reverse causation and limiting predictive value[9].

To our knowledge, only one prospective cohort, i.e., the UK Biobank (UKB), has hitherto been
used to discover predictive PD biomarkers. Based on this resource, a recent study analyzed
2,920 plasma proteins measured with Olink technology in up to 859 incident PD patients[10].
Although 38 candidate biomarkers were identified, the findings of that study remain
unvalidated in independent prospective cohorts. In addition to closing this gap, our study
represents a major advance by nearly tripling the number of protein markers (n=7,285;
SomaScan 7K array) analyzed in pre-diagnostic blood samples from ~4,600 participants in a
large, well-characterized case-cohort ('European Investigation into Cancer and Nutrition for
Parkinson's disease', EPIC4PD)[11] within the EPIC study[12,13]. Overall, EPIC4PD features up to
28 years of follow-up time and 574 specialist-confirmed incident PD diagnoses. Crucially, we
externally validated our top biomarkers in ~65,000 individuals, including >1,000 incident PD
cases, across three independent prospective cohorts. Overall, this resulted in the largest and
most comprehensive investigation of predictive biomarkers for PD to date, both in terms of
sample size and proteomic resolution. To assess these markers across the disease timeline
— including diagnosis and progression — we also incorporated independent SomaScan 7K
data from the Global Neurodegenerative Proteomics Consortium (GNPC; ~300 prevalent
cases and ~2,300 controls) and the Tracking PD cohort (~800 cases with progression data).
Using the top results from these analysis arms, we also performed enrichment and network
analyses to gain insights into biological pathways, and evaluated PD biomarker profiles in AD
and amyotrophic lateral sclerosis (ALS) to assess their potential as shared markers of
neurodegeneration (**Figure 1**). Finally, using machine-leaning we constructed and externally
validated a predictive protein risk score (PPRS) in EPIC4PD. This score improved risk
prediction decades before clinical PD onset. Combined with traditional risk factors and
markers from other molecular domains, the biomarkers identified in this study have the
potential to substantially advance ultra-early PD risk stratification and diagnosis paving the
way   for   early   treatment   and   prevention.

RESULTS

EPIC4PD case-cohort

In the discovery phase of this study (**Figure 1**), we leveraged data from the EPIC cohort to

build a large case-cohort (EPIC4PD) of 4,538 participants (including 574 incident PD cases;

Table 1) across 10 European centers in Spain, Italy, the Netherlands, the UK, and Germany,

combining deep proteomic profiling (6,382 proteins via 7,285 aptamers) in baseline, i.e, pre-

disease plasma samples, with long-term prospective follow-up. EPIC4PD participants had a

median baseline age of 53 years (range: 35–79), comprising 63% women (57% excluding the

Utrecht center, which recruited only women), and were followed for up to 28 years (median:

16 years). Among PD cases, the median time from blood sampling to diagnosis was 11 years

(range: 2–25), enabling biomarker discovery long before clinical onset. Consistent with

known PD risk profiles, PD cases were older at baseline (median: 59 vs. 52 years), more likely

male (58% vs. 40%, excluding Utrecht), less likely to be current smokers (15% vs. 25%), and

slightly more often overweight (64% vs. 60% with body mass index (BMI) ≥25) compared to

non-cases (**Supplementary Tables 1–2**).

Association analyses in the full EPIC4PD dataset

We used Cox proportional hazards regression models across 7,285 aptamers to identify

proteins associated with a future PD onset (**Supplementary Table 3**). In the basic model

(stratified by age in 5-year intervals, sex, and center) covering the full follow-up period (2–28

years), 17 proteins were significantly associated with PD risk after a false-discovery rate

(FDR) control of 0.05 (**Table 2, Supplementary Table 4**). We applied two approaches in the

discovery phase to address outliers: one excluded extreme values as potential noise, and the

other retained them via capping, as they may represent strong PD signals. Nine proteins

were FDR-significant in both approaches; for the other eight (six upon exclusion, two upon

capping), the alternative model still showed consistent, nominally significant associations

(mean ΔHR⏃=⏃0.03, maximum ΔHR=0.13; **Supplementary Figure 1**), supporting robustness

of our findings. For simplicity, we report only one result (from the better-performing model)

in the main text, with capped data labeled "cap"; full results are available in **Supplementary**

Table 3. Top proteins associated with PD incidence included VAMP3 (hazard ratio [per 1

standard deviation (SD) increase in $\log_{10}$-transformed protein levels]=1.26, p=1.46E-08),

TPPP2 (HR=0.70, p=8.52E-08), HPGDS (HR=0.73, p=8.59E-08), ALPL$_{cap}$ (HR=1.25, p=1.30E-07),

FCAR (HR=1.34, p=3.48E-07), and CERS5 (HR=1.23, p=5.64E-06; **Figure 2**, **Table 2**). All FDR-

significant associations remained stable after additional adjustment for key demographic
and lifestyle factors (education level, BMI, smoking, and physical activity), with minimal
impact on effect sizes (mean ΔHR=0.02, maximum ΔHR=0.07; **Supplementary Figure 1**,
Supplementary Table 4).

External replication of predictive biomarkers in the full follow-up period
Of the 17 FDR-significant biomarkers identified in EPIC4PD, replication data were available in
a total of 64,856 participants (including 1,034 incident PD cases) from three prospective
studies: the Gene/Environment Susceptibility–Reykjavik Study (AGES), Atherosclerosis Risk in
Communities study (ARIC), and UKB. Specifically, all 17 proteins were available in AGES
(5,090 participants, 121 cases; SomaScan 7K), 15 in ARIC (11,205 participants, 164 cases;
SomaScan 5K), and 8 in UKB (48,561 participants, up to 749 cases; Olink 3072 Explore;
Supplementary Table 5, **Figure 3**, **Supplementary Figure 2**). The other 9 proteins were not
measured in UKB, as the current Olink platform captures only ~30% of the proteins assayed
by SomaScan 7K. We also included independent SomaScan 7K-based data from prevalent
cases as 'indirect' replication. To this end, we re-analyzed proteomic profiles from 2,592
participants (335 prevalent PD cases and 2,257 controls) across three GNPC case-control
datasets (also see below for comparison of incident and prevalent PD), using similar
methodology as with our discovery phase analyses.
When interpreting the replication results, platform-related differences between Olink and
SomaScan must be considered. In line with the previous UKB study[10], we observed a global
protein downregulation in incident PD cases in our re-analyses of the UKB Olink data (i.e.,
87% of nominally significantly associated proteins). However, this pattern was not seen in
SomaScan-based datasets from EPIC4PD, AGES, or ARIC (proportion of downregulated
proteins: 43% to 56%; **Supplementary Table 6**), underscoring the challenges of cross-
platform comparisons.
Given the higher comparability of results from datasets generated using the same
technology, we first considered replication evidence in the SomaScan-based datasets (AGES,
ARIC, and GNPC). Overall, six of the 17 proteins — TPPP2, HPGDS, ALPL, MFAP5, OGFR, and
ACAD8 — showed strong evidence for replication, i.e., nominally significant evidence for
association in at least one dataset and, moreover, fully consistent effect estimates across all
independent studies with available data (**Figure 3**). Furthermore, VAMP3, GTF2A2, and FGF8
showed moderate evidence for replication, i.e., highly consistent effect directions across all

available datasets albeit without any replication dataset individually reaching nominal
significance (**Figure 3**, **Table 2, Supplementary Table 5**). Upon reviewing the replication
evidence in the UKB, the evidence of association was further substantiated for TPPP2,
HPGDS, MFAP, and OGFR, while ALPL, ACAD8, VAMP3, GTF2A2, and FGF8 were not
measured by Olink. Several additional proteins showed suggestive replication evidence in
individual datasets, but the overall replication evidence was more heterogeneous (**Table 2**,
Supplementary Figure 2, Supplementary Table 6).

In summary, nine of the 17 biomarkers (53%; ACAD8, HPGDS, TPPP2, OGFR, MFAP5, ALPL,
FGF8, VAMP3, GTF2A2) were replicated across different technologies, populations, and
study designs, reinforcing their specific predictive potential, and, more generally, support
the generalizability of our biomarker signals.

Biomarker associations relative to disease onset

Stratifying analyses by temporal proximity to PD diagnosis revealed remarkable biomarker
dynamics. In the window closest to disease onset (2-10 years; n=4,230 participants including
245 incident cases), three additional proteins — IL11, TCL1A, and TIMP1$_{cap}$ — emerged as
FDR-significant. In the more distal window (10-20 years; n=4,023 including 307 incident
cases), 19 additional proteins showed strong associations with PD incidence (**Figure 2, Table
2, Supplementary Table 4**). These proteins had not been identified as significant overall due
to negligible effects in the other time window (**Supplementary Table 3, Supplementary
Figure 2**). Dynamic biomarker patterns were further supported by HR trajectories derived
from 5-year sliding windows (**Figure 2, Supplementary Figure 3**). Together, these findings
demonstrate that key biomarkers for PD may emerge at distinct preclinical phases,
underscoring the value of deep proteomic profiling with extended follow-up to reveal
dynamic, stage-specific signatures of preclinical disease.

External replication of the temporal analysis results

Of the three newly emerging biomarkers from the proximal follow-up window (2-10 years
before diagnosis), TCL1A showed strong independent replication evidence and TIMP1
showed moderate support, while IL11 did not replicate (**Figure 3**, **Supplementary Figure 2,
Supplementary Table 5**). Among the 19 biomarkers emerging from the 10-20 year window,
GPC4, GSTA3, and LCN2 exhibited strong evidence of replication, and ABHD12 showed
moderate support (**Figure 3**). For LCN, we observed nominally significant evidence for

replication in ARIC with the same effect direction as in EPIC4PD. However, in UKB, LCN2 also

reached nominal significance (p=3.80E-03) but showed an inverse direction of effect (**Figure**

3, **Supplementary Table 5**). This discrepancy likely reflects methodological differences

between the SomaScan and Olink proteomic platforms. In line with this and the general

trend mentioned above, all but one biomarker (MAGEA8) were upregulated in EPIC4PD, but

in all but one instance (HEPACAM2) downregulated in UKB. Generally, replication datasets

were fewer in number and had smaller sample sizes within the shorter time windows

(**Methods** and **Supplementary Table 5**), which may partly explain the generally more modest

replication evidence observed.

Sex-stratified analyses

In EPIC4PD, 18% (3 of 17) of proteins significantly associated with PD risk in the full follow-up

period showed clear sex-specific effect size differences and significant interaction with sex

after FDR control. These proteins included NAMPT$_{cap}$ (ΔHR=−48%), FCAR (ΔHR=−42%), and

ALPL$_{cap}$ (ΔHR=−34%; **Supplementary Figure 1**, **Supplementary Table 7**).

Furthermore, sex-stratified proteome-wide analyses uncovered six additional proteins (RS1,

KRAS$_{cap}$, LYZ$_{cap}$, GBA3$_{cap}$, GJA1, AMN) FDR-significantly associated with PD risk in men and

two (CXCL11, ITGA6) in women, none of which showed strong associations in the opposite

sex (HRs 0.92–1.10, all $p \geq 0.05$; **Supplementary Figure 1**, **Supplementary Figure 4;**

Supplementary Table 4). Interaction analyses confirmed FDR-significant sex-based risk

modifications for all male-specific biomarkers except GJA1. However, the latter and CXCL11

still showed nominally significant evidence for interaction (**Supplementary Table 7**). The

results of these 11 FDR-significant proteins in the sex-stratified analyses remained stable

after adjusting for lifestyle variables and, in women, for menopausal status and

postmenopausal hormone therapy (**Supplementary Figure 1**, **Supplementary Table 4**).

KRAS$_{cap}$ and GJA1 demonstrated strong evidence of replication in men, while AMN (men)

and CXCL11 (women) provided moderate evidence for replication (**Figure 3**). The limited

sample sizes in the sex strata of the AGES and ARIC cohorts precluded analyses of interaction

with sex. In the UKB, 5 of the 11 candidate sex-specific biomarkers had been quantified;

however, none showed statistically significant associations in the sex strata, possibly

reflecting methodological differences between SomaScan and Olink platforms (see

Discussion). Collectively, these findings underscore the importance of accounting for sex-

specific effects in biomarker discovery, as such effects may reveal associations that remain
hidden in sex-combined analyses.

Inter-correlations of predictive biomarkers in EPIC4PD
Several FDR-significant biomarkers showed moderate inter-correlations (r=0.4-0.6) in
EPIC4PD, suggesting shared regulation or involvement in the same pathway. Correlations
were observed between MFAP5 and both HPGDS and TPPP2 (r=0.54 each) and between
LCN2 and LTF (r=0.60). FCAR also featured in several correlation clusters, underscoring its
broader connectivity (detailed in **Supplementary Figure 5** and **Supplementary Table 8)**.

Characterization of preclinical biomarkers in prevalent PD and PD progression
Next, we investigated whether the effects of the identified preclinical biomarkers extended
beyond the risk phase into the symptomatic stage of PD by leveraging the SomaScan 7K
proteomic data from 2,592 independent GNPC participants (335 prevalent cases and 2,257
controls; **Figure 3, Supplementary Table 9**; see the companion manuscript of Imam et al.[14]
for full dataset description). Of all 47 preclinical biomarkers detectable in GNPC, 7 (15%;
TPPP2, HPGDS, ALPL, NAMPT, GSTA3, KRAS, GJA1) were nominally significantly associated
with prevalent PD, and 4 (TPPP2, HPGDS, NAMPT, GSTA3) remained significant after FDR
control. All but NAMPT showed consistent effect directions. Overall, 38 (81%) of the 47 top
proteins and 125 (86%) of the 146 nominally significant aptamers results shared between
both traits showed concordant directions of effect — significantly more than expected by
chance (p=1.25E-5 and p=1.64E-19, respectively; one-sided exact binomial test; **Figure 3;**
Supplementary Table 9). In serum samples from the Tracking Parkinson's cohort (n=794), we
assessed associations between FDR-significant preclinical biomarkers and clinical outcomes
related to disease progression, using motor (Unified Parkinson's Disease Rating Scale Part III,
UPDRS-III) and cognitive (Montreal Cognitive Assessment, MoCA MoCA) scores in cross-
sectional and longitudinal mixed-effects models (**Figure 3**, **Supplementary Table 10**). Two
biomarkers, HPGDS (β=2.61, p=6.82E-04) and MFAP5 (β=1.31, p=1.49E-03), were FDR-
significantly associated with higher MoCA scores over time, indicating that lower levels of
these proteins predict both increased PD risk and faster cognitive decline. Associations
remained robust after adjusting for BMI and disease duration (data not shown). These
results demonstrate that a considerable fraction of preclinical biomarkers persist in their
dysregulation in prevalent PD, and a small subset is even associated with progression.

Comparing incident and prevalent disease settings, such as between EPIC4PD and GNPC, is

essential for determining which biomarkers are robust across the disease continuum and

which are specific to particular stages. This distinction enables identification of biomarkers

suitable for early detection versus those better suited for diagnosis or disease monitoring.

Comprehensive assessment of previously described biomarker candidates

Of 291 unique proteins previously linked to PD across methodologically diverse sources[10,15–

17], 191 proteins were assessable in the EPIC4PD data (**Supplementary Table 11**): Most

notably, 38 proteins had recently been reported as putative predictive PD biomarkers in the

UKB Olink study[10], with 27 also covered in our independent dataset. Of these, 11 (41%;

HPGDS, CD209, TPPP3, EPS8L2, FCRL1, BAG3, TNXB, IL13RA1, NEFL, PPY, RET) showed at

least nominally significant associations in one or more follow-up intervals. HPGDS also

represents a top biomarker in EPIC4PD (**Table 2**). The next two most significant proteins

were CD209 (best model for follow-up of 10-20 years: HR=0.75, p=1.32E-04) and TPPP3 (best

result: 2-28 years: HR=0.80, p=1.58E-03), which aligns well with TPPP2, one of the lead

findings in EPIC4PD (see Discussion). All but one (PPY) of the at least nominally significantly

associated biomarkers showed the same effect direction as in the previous study[10] despite

platform differences. Of the 127 candidate neurological biomarkers from the CNS NULISA

panel (Alamar, Inc), 106 were tested in EPIC4PD; of these, UBE2L3|UBB and CCL11

represented top biomarkers in EPIC4PD (**Table 2**). Other nominally significant findings

included for instance SNCA, DDC, NEFL, TREM2, GFAP, and TIMP3. Furthermore, PYDC1

nominated by a recent Mendelian randomization (MR) and colocalization study[18] was among

the top results in EPIC4PD suggesting a causative link to PD risk. Several other candidates

from an additional MR[16] or GWAS[17] showed nominal associations in EPIC4PD

(**Supplementary Table 11**).

Conversely, 5 of the 39 FDR-significant PD biomarkers identified in our non–sex-stratified

EPIC4PD analyses (CRYGD, LTF, HPGDS, TCL1A, and LCN2) were also included in the MR study

based on SomaScan data[16]. Of these, two biomarkers (CRYGD and LTF) showed nominal

evidence of a causal association with PD, suggesting that higher circulating levels may

increase disease risk, in line with the EPIC4PD findings (**Supplementary Table 12**). The

limited overlap in assessed proteins likely reflects the comparatively stringent analysis

criteria applied in that study [16].

Cross-disease comparisons

The 47 FDR-significant PD biomarkers identified in EPIC4PD were also evaluated in incident AD (n=1,926, including 652 cases) and ALS (n=4,715, including 187 cases) using Cox regression analyses in the EPIC4AD and EPICALS case-cohorts (**Supplementary Table 1**), respectively. Sixteen (34%) preclinical PD biomarkers showed at least nominally significant associations with AD and/or ALS, all with concordant effect directions. Correlation plots of hazard ratios showed alignment in effect size estimates (**Figure 3**). Notably, three PD proteins — RSPO2, SPAST$_{cap}$, PYDC1 — were FDR-significant for AD and also showed nominally significant associations with ALS (**Table 2, Figure 3, Supplementary Table 13**).

At the proteome-wide level, 17% of proteins nominally significantly associated with PD over the full follow-up period (non-sex-stratified) also showed associations with AD and/or ALS, whereas 83% appeared to be PD-specific. Among the shared proteins, the majority (68%) overlapped exclusively with AD, 25% with ALS, and 7% were common to all three neurodegenerative diseases (**Supplementary Figure 6**). Nominally significant preclinical AD biomarkers were significantly enriched among nominally significant PD biomarkers (p=1.19E-03; Fisher's exact test), while ALS biomarkers were not (p=0.107). Notably, 85 of 92 PD–AD and 33 of 39 PD–ALS shared proteins showed concordant effect directions (p=1.92E-18 and p=7.15E-06; exact binomial test; **Figure 3**). Additionally, among proteins nominally associated with PD, effect sizes modestly correlated with AD and ALS (Pearson's r=0.18 [95% CI: 0.11–0.25] and r=0.21 [0.14–0.28], respectively; **Figure 3**). While these comparisons highlight a largely PD-specific biomarker signature, they also point to partially shared preclinical pathways.

Functional characterization of preclinical PD biomarkers

Gene ontology (GO) enrichment analysis of suggestive PD biomarkers (n=154 proteins with p<1.0E-03 and consistent effect directions; see Methods) did not yield FDR-significant results but revealed 68 gene sets with strong nominal enrichment (p<1.0E-02), highlighting numerous biologically plausible and likely disease-relevant pathways based on prior evidence. Strikingly, despite the long time between blood draw and clinical diagnosis, we observed several well-established mechanisms in PD among the top 'biological processes' categories, including vesicle trafficking (e.g., endoplasmatic-reticulum-to-Golgi transport, vesicle docking), dopaminergic neuron differentiation, microtubule dynamics, and immune-related responses (e.g., to interleukin-6, cytokines, neutrophil-mediated immunity). Lastly,

several vitamin-related processes, including response to vitamin D, also emerged, pointing to

molecular pathways that were especially prominent in earlier PD research. Enrichments in

'cellular component' and 'molecular function' categories reinforced the role of vesicle-

mediated activity, while Reactome analysis further emphasized immune system

involvement, including antimicrobial peptides (**Supplementary Tables 14**).

Expression heatmaps across 50 human bulk tissues and single brain cell types based on RNA-

seq data revealed relatively high expression of several FDR-significant biomarkers in

peripheral and central immune-related tissues and cells compared to other tissue types

(**Supplementary Figures 7-8**). Protein-level data from the Human Protein Atlas supported

this observation (**Supplementary Figure 9**). Consistent with these findings, single-cell RNA-

seq–based enrichment analyses of FDR-significant and suggestive biomarkers in mice and

humans supported a role for immune cells in preclinical PD. In mouse cortex, suggestive

biomarkers showed nominally significant enrichment in microglia (**Supplementary Table 15**).

Analyses across 23 representative human cell types (including immune, neuronal, intestinal,

muscle, liver, and fibroblast cells) demonstrated nominally significant enrichment in

fibroblasts, monocytes and Kupffer cells, with borderline significance in granulocytes and

macrophages (**Supplementary Table 15**). Collectively, these single-cell RNA-seq–based

findings align with our Gene Ontology and Reactome pathway results, highlighting early

immune system involvement as a key feature of preclinical PD.

Interestingly, protein–protein interaction (PPI) analysis revealed that FDR-significant

biomarkers were significantly more likely to interact with GWAS-nominated PD risk genes[17]

than expected by chance (p=1.0E-04; permutation test; **Figure 3**, **Supplementary Table 16**).

Within this network, SNCA emerged as a central hub, exhibiting several direct edges with

FDR-significant biomarkers (**Figure 3**). Consistently, *SNCA* expression in both brain and

immune cells was significantly correlated with several of these biomarkers (**Supplementary**

Table 17). In brain, strong correlations (r≥0.5) were observed with RS1, RSPO2, and OSTF1,

and in immune cells, with LYZ, VAMP3, F13A1, and FCAR. Furthermore, SNCA showed

significant correlations with FDR-significant preclinical biomarkers more often than expected

by chance (p=1.12E-02 for immune cells; p=9.1E-02 for brain cells; permutation t test). These

findings provide converging evidence that the identified preclinical biomarkers capture early

pathophysiological processes consistent with independent lines of prior research.

Finally, a semi-systematic literature search revealed prior functional evidence for a major
part of the 47 preclinical PD biomarkers (details in the **Supplementary Material**
[**Supplementary Table 18**]).

Druggability assessment of preclinical biomarkers
Given their potential pathophysiological implications, we next evaluated whether any of the
47 FDR-significant preclinical PD biomarkers represent druggable targets using the Open
Targets database[19]. Twenty-one proteins (45%) showed at least one supporting line of
evidence for interaction with small-molecule drugs (**Supplementary Table 19**). Notably, four
proteins — NAMPT, KRAS, CD3G, and F13A1 — were associated with compounds currently
undergoing clinical trials in non-neurological diseases (mostly cancer), underscoring their
translational potential. These findings indicate that a substantial share of preclinical PD
biomarkers may be pharmacologically modifiable.

Disease prediction
To assess predictive utility, we applied least absolute shrinkage and selection operator
(LASSO)-based machine learning in EPIC4PD with repeated subsampling and regularization.
Across 100 subsamples, the most frequently selected proteins were extracted with their
corresponding average weights (**Supplementary Table 20**). As external validation, we
calculated weighted predictive protein risk scores (PPRS) in the AGES cohort (n=5,090; 121
incident PD cases), leveraging the shared SomaScan 7K platform. Risk scores were based on
EPIC4PD results, varying by the number of proteins and using average LASSO-derived
coefficients. Given the marked sex differences in EPIC4PD biomarker signatures, primary
models were developed separately for men and women, with additional combined models
adjusted for sex for comparison (**Supplementary Tables 20-21**). In men (n=2,136; 75 PD
cases), the best-performing PPRS (50 proteins+age, C-index: 0.63, SE: 0.03) largely
outperformed the age-only model with $\Delta C=0.08$. Nine proteins that were FDR-significant in
the univariate Cox models in EPIC4PD were also included in this PPRS (including GSTA3, RS1,
and HPGDS; **Supplementary Table 20**). In women (n=2,954; 46 cases), the best PPRS (20
proteins+age, C-index: 0.61; SE: 0.04) improved prediction similarly with $\Delta C=0.07$. This PPRS
included three (CXCL11, TPPP2, and HPGDS) of the univariate analyses in EPIC4PD. As
expected, improvement of risk prediction in the combined cohort was attenuated ($\Delta C=0.03$
for best score). These findings emphasize the necessity of incorporating sex-stratified

analyses into disease prediction research to enable the development of high-precision risk

models.

DISCUSSION

In this large, prospective, and multi-center proteomic study, we identified and independently validated novel plasma biomarkers predictive of PD onset up to two decades or more before clinical diagnosis. Using the high-resolution SomaScan 7K platform in pre-diagnostic samples from over 4,500 EPIC4PD participants, we discovered 47 proteins significantly associated with incident PD. Several top markers — TPPP2, HPGDS, ALPL, MFAP5, OGFR, ACAD8, TCL1A, GPC4, GSTA3, LCN2, KRAS, and GJA1 — showed strong replication across incident (AGES, ARIC, UKB) and prevalent (GNPC) PD cases, underscoring their robustness across platforms and populations. Importantly, owing to the much larger proteomic resolution our study uncovered numerous novel PD biomarkers not assayed in the previous analyses in the UKB[10]. In addition, while we observed that pre-clinical protein biomarker profiles are partially shared between PD and other neurodegenerative diseases (i.e., AD and ALS), delineated PD biomarker profile appears to be largely disease-specific. Overall, our study delivers the most comprehensive proteomic resource for preclinical PD to date. It is unique by incorporating diverse preclinical validation cohorts, by spanning the full disease course, and by demonstrating some overlap with the preclinical phase of other neurodegenerative disorders. As such it sets a new benchmark for biomarker discovery in neurodegeneration.

Our findings offer several new key insights: First, predictive PD biomarkers can be reliably identified in blood many years, even decades, before diagnosis. This relates to signals such as HPGDS, MFAP5, OGFR, and ACAD8, which remain stable across different platforms and populations. Second, we also observed dynamic, stage-dependent biomarker patterns: while some proteins persist throughout all stages, others appear only within certain time windows before diagnosis (such as TCL1A, GPC4, GSTA3, and LCN2), possibly reflecting underlying pathophysiological shifts. This temporal resolution is critical for distinguishing genuine early biomarker signals from late-stage or treatment-related changes. Third, we observed evidence for sex-specific effects for several biomarkers in EPIC4PD, an observation not seen in our re-analysis of the Olink-based UKB data. This suggests that some sex-dependent protein isoforms — such as specific glycosylation patterns or cleavage products — may be captured by SomaScan but not by Olink's dual-antibody format, which relies on simultaneous binding to two defined epitopes[20]. In this context, it is striking that in the previous UKB study[10], all top preclinical biomarkers were *decreased* in incident PD cases.

464 While we confirmed this pattern in our re-analysis of the UKB data, it was not observed in

465 any of the SomaScan-based datasets. At the same time, the substantial concordance in

466 effect directions across the independent SomaScan-7K-based data from EPIC4PD and GNPC

467 supports the validity of our findings. Thus, the observed discrepancies between this study

468 and UKB[10] likely reflect methodological differences between proteomic platforms used.

469 While recent evidence suggests that the latest SomaScan platforms provide higher

470 measurement precision in comparison to Olink[21–25], importantly, the two platforms capture

471 partly distinct protein features, underscoring their complementary strengths[21]. A

472 comprehensive understanding of these differences will require benchmarking against mass

473 spectrometry. Until then, it is important to recognize that genuine protein associations may

474 fail to replicate or even show opposite effects when comparing results across these two

475 technologically different platforms.

476 Fourth, we observed high concordance (>80%) in effect size directions between preclinical

477 and clinical biomarkers across two independent datasets (EPIC4PD and GNPC, both

478 SomaScan 7K), supporting the robustness of our findings and providing indirect replication.

479 These comparisons are essential to identify which biomarkers are relevant across all stages

480 vs. those that are stage-specific, informing their use for early detection, diagnosis, or

481 monitoring. Fifth, we were in the unique position to probe for an overlap of preclinical

482 biomarker profiles of PD and two other neurodegenerative diseases (AD and ALS). About

483 one-third of PD biomarkers also showed consistent associations with incident AD and/or

484 ALS, including RSPO2, SPAST, and PYDC1. While effect sizes correlated modestly across

485 diseases, the clear enrichment of shared biomarkers — especially between PD and AD —

486 suggests partially overlapping preclinical mechanisms. Notwithstanding these overlaps, we

487 emphasize that most identifed biomarkers were specific to PD.

488 Sixth, this latter conclusion is confirmed by a wide array of *in silico* analyses supporting the

489 biological plausibility of many of our biomarker findings. For instance, we saw an

490 overrepresentation of key PD-relevant processes, including vesicle trafficking, dopaminergic

491 neuron biology, and immune signaling. Thus, it appears that these disease-related

492 mechanisms are already active and detectable in blood over two decades before diagnosis.

493 Furthermore, cell-type enrichment analyses implicated the involvement of microglia and

494 peripheral immune cells already in the earliest disease phases, aligning with current

495 neuroinflammation models of PD[26,27]. Moreover, our PPI analyses suggest that the preclinical

biomarkers interacted more frequently than expected with known PD proteins and
significantly correlated with *SNCA* expression, strongly emphasizing their functional
relevance to the disease. Along these lines, several of our newly detected preclinical
biomarkers had been implicated in biomarker as well as in functional studies in PD before.
For example, TCL1A[28], GPC4[29], LCN2[30], AMN[31], CXCL11[32], CUL4B[33], FCAR[34], BECN1[35], and
NAMPT[36] have previously been reported as potential blood biomarkers in prevalent PD in
studies with smaller sample sizes. In addition, some of the preclinical PD biomarkers were
reported to show differential expression in post-mortem brain tissue from PD patients
compared to controls (e.g., LCN2[37], GJA1[38], TIMP1[39], AMN[31]). Lastly, several of our top
biomarker proteins are implicated in microtubule dynamics (TPPP2), vesicle trafficking in the
presynapsis (VAMP3), mitochondrial functions (ACAD8), dopaminergic neuronal function and
maturation (GPC4, FGF8) and immune functioning/neuroinflammation (TCL1A, CXCL12),
which are all highly relevant in PD pathophysiology[40]. A detailed summary of key
experimental findings and supporting evidence, can be found in the **Supplementary**
Material. Seventh, our druggability assessments revealed that nearly half of the FDR-
significant biomarkers show evidence for small-molecule interactions. While blood-based
biomarkers of brain diseases (like PD) do not automatically translate into therapeutic
targets, this overlap may help prioritize candidates for future functional studies and
repurposing efforts.

Last, we developed a sex-specific protein risk score (n=50 men, n=20 women), which showed
robust predictive value in external validation within the AGES cohort and outperformed sex-
combined models. These findings underscore both the potential of proteomic risk profiling
for early PD risk stratification and the importance of considering sex differences.
Incorporating genetic, lifestyle, and environmental factors is expected to further improve
prediction. Along these lines, existing tools, such as the updated MDS criteria (specialist
settings) and the PREDICT-PD algorithm (broader screening)[41,42], show promise but remain
insufficient, particularly for detecting preclinical PD more than five years before diagnosis
(e.g., ref. [43]). These tools are continuously evolving, and integrating our protein biomarkers
alongside sex-stratified analyses offers a logical next step to improve predictive accuracy.

Our study has several strengths, including representing the largest collection of incident PD
proteomic datasets to date, an exceedingly long-term follow-up, rigorous case
ascertainment, the inclusion of several external datasets ensuring population and platform

cross-validations, as well as extension to other disease phenotypes and diseases.
Notwithstanding, our study also has several potential limitations. First, use of distinct
proteomic platforms with different technologies, particularly SomaScan versus Olink, and
coverages, comparatively limited case numbers despite large replication cohorts, usage of
different blood sample types (citrate plasma, EDTA plasma, or serum) as well as differences
in study design (e.g., recruitment, case ascertainment, follow-up) may have contributed to
non-replication of some biomarkers. Second, as outlined above, while the SomaScan 7K
assay offers extensive coverage, it is semi-quantitative; signal changes may reflect different
proteoforms rather than absolute protein levels, complicating interpretation. Mass
spectrometry-based approaches are needed to clarify the underlying biology. Third, although
we adjusted for key covariates in sensitivity analyses, residual confounding remains possible.
Fourth, lacking neuropathological confirmation, some PD cases may have been misclassified
— a common problem in large cohorts and a general limitation in epidemiological studies.
However, given that medical charts of PD cases were reviewed by clinical specialists, the risk
of misclassification in EPIC4PD is likely lower than in cohorts such as UKB. Finally, all datasets
consisted exclusively or predominantly of non-Hispanic White participants. While the ARIC
study also included a subset of Black participants (n=2,625) and their exclusion did not affect
effect estimates, the sample size was too limited to allow for dedicated ethnicity-specific
analyses of this subset. Thus, while our findings are likely generalizable to populations of
European ancestry, their applicability to other ethnicities requires further assessment.

In conclusion, our study identifies and validates robust blood-based biomarkers that predict
PD several decades before clinical onset. Our results underscore the importance of applying
prospective cohort designs with incident case ascertainment to detect truly preclinical
biomarkers. By capturing early molecular changes, our work lays the foundation for
developing prevention strategies using precision medicine approaches in PD and potentially
other neurodegenerative diseases.

Acknowledgements

The authors thank all EPIC participants and the countless scientists who have contributed to

the EPIC cohort over the past 30 years. We thank the National Institute for Public Health and

the Environment (RIVM), Bilthoven, the Netherlands, for contributing cases and ongoing

support to the EPIC study. We sincerely thank Bertrand Hemon for his assistance with data

management, and Prof. Paolo Vineis, Prof. Beate Ritz, Prof. Martin Wolkewitz, Prof. Klaus

Berger, Prof. Valentina Gallo, Dr. Mark Frasier, and Dr. Lazaros Belbasis for helpful

discussions.

Data access

Data can be accessed by external researchers after approval by the EPIC4ND working group

and the EPIC steering committee. Potential collaborators can contact the EPIC4ND working

group chair, Christina Lill (christina.lill@uni-muenster.de and clill@ic.ac.uk) and EPIC

administrator Sherry Morris (epicadmin@imperial.ac.uk).

Funding

Updates of the PD case ascertainments, generation and processing of proteomic data were

funded by the Michael J Fox Foundation (#008994 to C.M.L. and E.R.). Part of the proteomic

data were also generated with funding from the Cure Alzheimer's Fund (to C.M.L. and L.B.),

and the 'CReATe- Clinical Research in ALS and Related Disorders for Therapeutic

Development' Consortium (to C.M.L. and L.B.). CReATe (U54 NS092091) is part of the Rare

Diseases Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases

Research (ORDR), NCATS and funded through collaborations between NCATS, NINDS, and

the ALS Association. Intramural funding was provided by the Interdisciplinary Centre for

Clinical Research, University Münster (to C.M.L.). Additional funding was supplied by the

Interdisciplinary Centre for Clinical Research, University Münster (to C.M.L., Lil3/001/25).

C.M. Lill was supported by the Heisenberg program of the DFG (DFG; LI 2654/4-1).

The coordination of EPIC-Europe is financially supported by International Agency for

Research on Cancer (IARC) and also by the Department of Epidemiology and Biostatistics,

School of Public Health, Imperial College London which has additional infrastructure support

provided by the NIHR Imperial Biomedical Research Centre (BRC). The national cohorts are

supported by Associazione Italiana per la Ricerca sul Cancro-AIRC-Italy, Italian Ministry of

Health, Italian Ministry of University and Research (MUR), Compagnia di San Paolo (Italy);

Dutch Ministry of Public Health, Welfare and Sports (VWS), the Netherlands Organisation for

Health Research and Development (ZonMW), World Cancer Research Fund (WCRF), (The

Netherlands); Instituto de Salud Carlos III (ISCIII), Regional Governments of Andalucía,

Asturias, Basque Country, Murcia and Navarra, and the Catalan Institute of Oncology - ICO

(Spain); Cancer Research UK (C864/A14136 to EPIC-Norfolk; C8221/A29017 to EPIC-Oxford),

Medical Research Council (MR/N003284/1, MC-UU_12015/1 and MC_UU_00006/1 to EPIC-

Norfolk; MR/Y013662/1 to EPIC-Oxford) (United Kingdom). Previous support has come from

"Europe against Cancer" Programme of the European Commission (DG SANCO). SomaScan®

data were generated under Master Research Agreement, 14th December 2021, between

Imperial College London and SomaLogic Inc. SomaLogic were not involved in analyzing or

interpreting the data; or in writing or submitting the manuscript for publication.

National Institute on Aging (NIA) contracts N01-AG-12100 and HHSN271201200022C (for Vi.

G.) and Althingi (the Icelandic Parliament) financed the AGES-Reykjavik study. IHA and

Novartis have collaborated on proteomics research since 2012. This study was also funded

by the NIA (1R01AG065596-01A1 to Vi. G., 2R01AG065596-03 to Va.G.), the University of

Iceland Postdoctoral Fund (to E.A.F.) and the Icelandic Research Fund (2511008-051 to

Va.G.). This research was supported, in part, by the Intramural Research Program (IRP) of the

NIA. K.A.W. and F.L. are supported by the NIA IRP. ARIC is carried out as a collaborative study

supported by National Heart, Lung, and Blood Institute (NHLBI) contracts (75N92022D00001,

75N92022D00002, 75N92022D00003, 75N92022D00004, 75N92022D00005). The ARIC

Neurocognitive Study was additionally supported by U01HL096812, U01HL096814,

U01HL096899, U01HL096902, and U01HL096917 from the NIH (NHLBI, NIA, National

Institute of Neurological Disorders and Stroke [NINDS], and National Institute on Deafness

and Other Communication Disorders [NIDCD]).

Disclaimer: Where authors are identified as personnel of the International Agency for

Research on Cancer / World Health Organization, the authors alone are responsible for the

views expressed in this article and they do not necessarily represent the decisions, policy or

views of the International Agency for Research on Cancer / World Health Organization.

Authors' contributions

Study concept and supervision: LB, PF, MJG, ER, CML; acquisition/contribution of data: SM,

JMH, MG, AJ-Z, MJS, CT-S, NC-C, AV, DP, SS, TK, NW, RK, RT, RV, SP, GM, CS, NF, GNPC, VK,

ViG, HG, LM, LMW, IT, VaG, KAW, PF, ER, MJG, CML, data analysis and interpretation: JH, AS,

SM, EAF, FL, VV, RM, RK-L, VD, OO, LD, FH, YZ, FA, KSB, PMK, JMH, NW,TH, SB, AE, MH, VaG,

LB, OR, LMW, IT, ViG, KAW, PF, ER, MJG, CML; drafting the manuscript: JH, SM, CML. Critical

revision of the manuscript for content: all co-authors

Competing interests

N.F. is an employee and stockholder of Novartis. K.A.W. is an Associate Editor at Alzheimer's

& Dementia, a member of the Editorial Board of Annals of Clinical and Translational

Neurology, and on the Board of Directors of the National Academy of Neuropsychology.

K.A.W. and I.W. have given unpaid seminars on behalf of SomaLogic. None of the other

authors reports any competing interest.

Legends to figures

Figure 1. Visual summary of study design.

<u>Legend.</u> This study leveraged plasma proteomics from 4,538 individuals in the 'European Prospective Investigation into
Cancer and Nutrition for Parkinson's disease' case-cohort (EPIC4PD) to discover preclinical protein biomarkers of
Parkinson's disease (PD). Using the SomaScan 7K platform, 7,285 aptamers were analyzed across multiple time windows.
Identified biomarkers were externally validated in three large cohorts ('Age, Gene/Environment Susceptibility–Reykjavik
Study' [AGES], 'Atherosclerosis Risk in Communities' study [ARIC], and 'United Kingdom Biobank' [UKB]) and assessed in
clinical PD cases from the 'Global Neurodegenerative Proteomics Cohort' [GNPC] and the longitudinal 'Tracking Parkinson's
disease' cohort. Functional characterization included pathway and cell-type enrichment, protein-protein networks, cross-
trait analyses with Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Predictive protein risk scores were
calculated in EPIC4PD and externally validated in AGES.

Figure 2. Cox proportional hazard regression analyses across different time-windows in
EPIC4PD.

<u>Legend.</u> Association results of preclinical protein biomarkers with incident Parkinson's disease across different follow-up
windows in EPIC4PD. Panels **A–C**: effect estimates for three time windows: full follow-up (2–28 years), proximal (2–10
years), and distal (10–20 years). **(D)** summary of associations of significant biomarkers (false-discovery rate of 0.05 in at
least one time-window) across all follow-up periods.

Figure 3. Validation and characterization of top preclinical biomarkers

<u>Legend.</u> **(A)** Forest plot of results of preclinical biomarkers for incident PD in the EPIC4PD case-cohort, the 'Age,
Gene/Environment Susceptibility–Reykjavik Study' (AGES), the 'Atherosclerosis Risk in Communities' study (ARIC), and
'United Kingdom Biobank' [UKB] cohorts. **(B)** Comparison of top preclinical PD biomarkers with their associations in
prevalent PD within the 'Global Neurodegenerative Proteomics Cohort' (GNPC); left: false-discovery rate (FDR)-significant
proteins from EPIC4PD; right: nominally significant proteins. Color-coding refers to risk (red) or protective (blue) effects in
GNPC. **(C)** Cross-disease analysis of preclinical PD-associated proteins compared to incident Alzheimer's disease (AD) and
amyotrophic lateral sclerosis (ALS) in EPIC4AD and EPIC4ALS. The top panels display all FDR-significant preclinical PD
proteins from the full follow-up analysis, while the bottom panels show proteins with nominal significance (p<0.05). Protein
names in orange indicate nominal significance in AD (top left) or ALS (top right). Orange bolded names indicate FDR-
significant proteins. For each disease, the bottom right plot illustrates the correlation of effect estimates using 'mirrored'
beta values (see Methods). **(D)** Protein-protein interaction network of FDR-significant predictive proteins (black border) and
GWAS-identified hits (no border). Eight clusters were identified using igraph's greedy optimisation of modularity. Node size
increases for nodes with 10 or more edges, proportional to the number of edges. **(E)** Integrated overview of datasets for
validation and characterization of FDR-significant biomarkers across different proteomic and transcriptomic layers.

Table 1. Overview of cohort datasets included in this study

Cohort	Population	Phenotype	Platform	Cases			Non-cases		N total
				Number (% women)	AAE (range)	AAD (range)	Number (% women)	AAE (range)	
EPIC4PD	Europe	incident PD	SomaScan 7K	574 (45%)	59 (38-77)	71 (45-89)	3,964 (66%)	52 (35-79)	**4,538**
ARIC	USA	incident PD	SomaScan 5K	164 (41%)	59 (48-68)	75 (56-87)	11,041 (56%)	57 (46-70)	**11,205**
AGES	Iceland	incident PD	SomaScan 7K	121 (38%)	78 (69-88)	84 (72-93)	4,969 (58%)	78 (68-98)	**5,090**
GNPC	Europe, USA	prevalent PD	SomaScan 7K	335 (37%)	75 (49-90)	-	2,257 (60%)	71.5 (27-90)	**2,592**
TRACKING PD	UK	PD progression	SomaScan 7K	794 (34%)	66 (38-85)*	66 (38-85)	-	-	**794**
EPIC4AD	Europe	incident AD	SomaScan 7K	652 (71%)	59 (36-69)	78 (53-93)	1,274 (63%)	49 (35-69)	**1,926**
EPIC4ALS	Europe	incident ALS	SomaScan 7K	187 (57%)	58 (38-76)	73 (48-95)	4,528 (66%)	52 (35-79)	**4,715**
UK Biobank	UK	incident PD	Olink Explore 3072	749 (37%)	64 (41-70)	71 (44-83)	47,812 (54%)	58 (40-70)	**48,561**
TOTAL				**3,572**			**70,523**		**74,095**

659
660 <u>Legend.</u> This table presents the cohort datasets included in the study. AAE = median age at examination (baseline), AAD = median age at diagnosis. Note that the individual EPIC-derived case-
661 cohorts (EPIC4PD, EPIC4AD, EPIC4ALS) the vast majority of non-cases, thus the total number of non-cases is not the sum of non-cases of the individual datasets. See Methods for full cohort name
662 abbreviations. *Mean age at visit 1.

663 **Table 2. Plasma protein biomarkers significantly associated with future onset of Parkinson's disease**

Protein	HR (95% CI)	p	q	Replication	Cross-disease	Prior evidence
2-28 years of follow-up						
VAMP3	1.26 (1.16-1.36)	1.46E-08	1.07E-04	moderate		
TPPP2	0.70 (0.61-0.80)	7.06E-08	3.15E-04	**strong**		
HPGDS	0.73 (0.65-0.82)	8.59E-08	2.09E-04	**strong**	AD	
ALPL$_{cap}$	1.25 (1.15-1.36)	1.30E-07	3.16E-04	**strong**		
FCAR	1.34 (1.20-1.50)	3.48E-07	6.34E-04	suggestive		Irmady et al., 2023[44]
CERS5	1.23 (1.12-1.34)	5.64E-06	6.85E-03	suggestive	ALS	
MFAP5$_{cap}$	0.73 (0.64-0.84)	1.14E-05	1.38E-02	**strong**		
RSPO2	1.19 (1.10-1.29)	2.09E-05	2.10E-02	suggestive	**AD**, ALS	
CD3G	1.19 (1.10-1.29)	2.30E-05	2.10E-02	suggestive		
GTF2A2$_{cap}$	1.22 (1.11-1.34)	2.30E-05	2.40E-02	moderate		
LTF	1.28 (1.14-1.43)	3.21E-05	2.34E-02		AD	
NAMPT$_{cap}$	1.28 (1.14-1.44)	4.51E-05	3.65E-02		ALS	Santiago et al., 2016[45]
OGFR	0.77 (0.68-0.87)	5.04E-05	3.67E-02	**strong**	AD	
FGF8	1.21 (1.10-1.33)	5.75E-05	3.46E-02	moderate		
PSG6	1.25 (1.12-1.39)	6.17E-05	3.46E-02			
ACAD8	1.18 (1.09-1.28)	7.05E-05	3.65E-02	**strong**	**AD**	
CRYGD	1.20 (1.10-1.32)	7.52E-05	3.65E-02			
2-10 years of follow-up						
TIMP1$_{cap}$	0.72 (0.62-0.83)	4.52E-06	1.65E-02	moderate		
IL11	1.30 (1.15-1.47)	2.04E-05	4.23E-02			
TCL1A	0.71 (0.61-0.83)	2.23E-05	4.23E-02	**strong**		Kedmi et al., 2011[46]
10-20 years of follow-up						
GUCA1B$_{cap}$	1.31 (1.18-1.45)	3.95E-07	1.44E-03			
UBE2L3│UBB$_{cap}$	1.29 (1.16-1.42)	6.08E-07	1.48E-03			

DCAF12	1.24 (1.12-1.37)	2.63E-05	2.47E-02			
GPC4$_{cap}$	1.26 (1.13-1.40)	2.80E-05	3.33E-02	**strong**		Tatenhorst et al., 2024[47]
BECN1	1.26 (1.13-1.40)	2.92E-05	2.47E-02			Miki et al., 2018[48]
HEPACAM2$_{cap}$	1.25 (1.12-1.39)	3.05E-05	3.33E-02	suggestive		
F13A1∣F13B$_{cap}$	1.34 (1.17-1.54)	3.20E-05	3.33E-02			
ABHD12	1.25 (1.12-1.38)	3.37E-05	2.47E-02	moderate		
IRAG2	1.24 (1.12-1.37)	3.38E-05	2.47E-02		AD	
TAFA4$_{cap}$	1.25 (1.12-1.39)	5.93E-05	3.93E-02			
GSTA3	1.23 (1.11-1.37)	6.08E-05	3.69E-02	**strong**	AD	
SPAST$_{cap}$	1.24 (1.11-1.38)	7.94E-05	4.45E-02		**AD**, ALS	
CUL4B	1.32 (1.15-1.51)	9.85E-05	4.22E-02			Yao et al., 2022[33]
OSTF1	1.30 (1.14-1.49)	9.92E-05	4.22E-02			
PYDC1	1.24 (1.11-1.38)	1.07E-04	4.22E-02		**AD**, ALS	D. Torshizi et al., 2024[18]
LCN2	1.30 (1.14-1.49)	1.10E-04	4.22E-02	**strong**		Fan et al., 2024[30]
OTX2	1.27 (1.13-1.44)	1.10E-04	4.22E-02		AD	
MAGEA8	0.66 (0.54-0.82)	1.16E-04	4.22E-02			
ZNF41	1.22 (1.10-1.35)	1.32E-04	4.57E-02			
Men						
RS1	1.42 (1.22-1.65)	4.34E-06	9.10E-03		**AD**	
KRAS$_{cap}$	1.34 (1.17-1.53)	1.30E-05	1.89E-02	**strong**		
LYZ$_{cap}$	1.37 (1.19-1.59)	2.06E-05	2.50E-02			
GBA3$_{cap}$	1.33 (1.16-1.52)	3.91E-05	3.17E-02		**AD**	
GJA1	1.32 (1.16-1.50)	3.70E-05	3.37E-02	**strong**	**AD**	
AMN	1.40 (1.19-1.64)	5.07E-05	3.69E-02	moderate	ALS	Elango et al., 2023[31]
Women						
ITGA6	1.27 (1.14-1.42)	1.87E-05	4.29E-02	suggestive		
CXCL11	0.69 (0.58-0.82)	2.34E-05	5.67E-02	moderate		Hepp et al., 2023[32]

<u>Legend.</u> This table presents all plasma proteins showing significant (false discovery rate [FDR]=0.05) association with incident Parkinson's disease (PD) in Cox proportional hazard regressions in the
EPIC4PD case-cohort stratified for center, sex (where non-sex-stratified) and 5-year age categories. Analyses were conducted for the entire follow-up period (2–28 years), as well as for proximal
(2–10 years) and distal (10–20 years) time windows before disease onset or censoring, and additionally analyzed per sex stratum over the full follow-up. <u>Strong evidence for replication</u>: At least
one nominally significant replication (for SomaScan in the same effect direction; for Olink, direction not required), and all additional SomaScan-based datasets showing effect estimates in the
same direction. <u>Moderate evidence for replication</u>: Effects observed in the same direction in all (at least two) SomaScan datasets datasets, but non-significant results, or alternatively, one
nominally significant SomaScan-based replication result (same direction), another SomaScan dataset showing the same and one showing an opposite direction. <u>Suggestive evidence for replication</u>:
One nominally significant replication result (same direction for SomaScan, for Olink, direction not required) but heterogeneous effect directions among remaining datasets, or only two SomaScan
datasets with consistent (but non-significant) effects. Cross-disease=at least nominally significant (uncorrected p<0.05) associations with instantaneous risk of Alzheimer's disease (AD) and
amyotrophic lateral sclerosis (ALS) based on EPIC4AD and EPIC4ALS, respectively. <u>Prior evidence:</u> publications describing differential protein and/or mRNA levels in blood in (always prevalent) PD
patients compared to controls. Note that these were always in line with effect directions in EPIC4PD. HR=hazard ratio; CI=95% confidence interval; q=FDR-adjusted p-value (FDR=0.05). Bolded
words for 'cross-disease' indicate significance at FDR=0.05. Note that from both outlier handling approaches, i.e., excluding outliers beyond 5 standard deviations from the log-mean or capping
these outliers at the value of 5 standard deviations (indicated as "cap"), only the more significant result (smaller q) is shown. However, in all instances, at least nominally significant evidence was
also observed for the alternative outlier removal method.

METHODS

Discovery cohort and study design

The EPIC cohort is a large multi-center prospective study that recruited 519,978 participants

(70.5% women, mostly aged 35-70 years at baseline) from 23 centers across ten European

countries. With approximately 30 years of follow-up, EPIC was originally established to

explore the relationships between diet and cancer, but it has since expanded to study other

chronic conditions, including neurodegenerative diseases[12,13]. Briefly, baseline data including

information on diet, physical activity, alcohol and tobacco use, past and current illnesses,

reproductive history, and anthropometric measurements were collected between 1991 and

2000. Citrate plasma samples from ~75% of all participants were obtained using

standardized protocols, then aliquoted and stored long-term in liquid nitrogen (−196 °C) at a

central biobank housed at the International Agency for Research on Cancer (IARC)/World

Health Organization in Lyon, France. Since baseline recruitment, participants have been

followed up regularly by data linkage and/or questionnaires at each center. The EPIC study

was approved by the ethical committee of IARC and by the ethical review boards of each

participating study center. All participants signed a written informed consent.

The 'EPIC for Parkinson's disease' case-cohort (EPIC4PD) analyzed in this study is embedded

within EPIC and aims to prospectively identify molecular biomarkers in PD[11]. The case

ascertainment protocol has been described previously[11,49]. It was based on a source

population of 157,288 subjects from ten EPIC centers across five European countries

including Spain (Murcia, Navarra, and San Sebastian), Italy (Florence, Turin, and Varese),

Netherlands (Utrecht and Bilthoven), UK (Norfolk/Cambridge), and Germany (Heidelberg).

Potential cases were ascertained based on data linkage through a combination of center-

specific methods using hospital records, general practitioner records, mortality records, drug

repositories, and questionnaire data followed by re-review of medical records by expert

neurologists for PD. Since the initial ascertainment, 163 incident PD cases were added

following an update of the case ascertainment in selected centers (Heidelberg, Florence,

Varese, Turin, Utrecht, Bilthoven)[11]. The subcohort for EPIC4PD was randomly drawn from

these centers from EPIC-interact, which is a random subcohort within EPIC[50]. The data freeze

for the current project was set to the time point of diagnosis of the last patient per center.

For the purpose of identifying predictive PD biomarkers, we applied a washout phase after

blood draw of two years prior to diagnosis to avoid reverse causation resulting in an
exclusion of 23 PD patients.

Generation and quality control of proteomic data in EPIC4PD

Protein abundances were measured in citrate plasma samples using the SomaScan 7K (v4.1)
platform (SomaLogic, Inc.). SomaScan is a high-throughput proteomic platform that uses
modified nucleotides (Slow Off-rate Modified Aptamers — SOMAmers) which specifically
bind to protein targets and quantifies them in relative fluorescence units (RFUs) using DNA
microarray[51]. The 7K version quantifies 7,596 aptamers targeting 6,432 unique proteins[52].
Measurements of overall 17,841 EPIC participants were performed at SomaLogic (Boulder,
CO, USA) as previously described. Participants included also individuals who were selected
for other endpoints (such as cancer). All samples were processed in a single procedure.
SomaScan assays were performed on 96-well plates, with 11 control wells per plate used to
monitor batch effects, accuracy, precision, and background. Each plate included five pooled
calibrator replicates, three quality control (QC) replicates, and three buffer replicates. In
addition, 233 replicates of one EPIC QC sample were included. Readout was conducted using
Agilent hybridization and scanning technology. To control readout variability, twelve
hybridization control aptamers were added during elution. Initial QC was conducted by
SomaLogic and included normalization of protein RFUs based on the following steps:
hybridization normalization, intraplate median normalization, plate scaling and calibration,
and adaptive normalization to a population reference.

We computed intraclass correlation coefficients (ICCs) for all 7,596 aptamers based on the
233 EPIC replicate measurements. Aptamers were removed if they were not a protein (n=46)
[Hybridization Control Elution (n=12), non-biotin (n=10), non-cleavable (n=4), spuriomer
(n=20)] or non-human (n=261). Aptamers were further excluded if both (i) the ICC was below
0.5 and (ii) if the aptamer levels were below the limit of detection (LOD) in more than 90% of
the samples (n=4). If the measured value of an aptamer was below the LOD, it was set to
LOD/2. The final number of quality-controlled aptamers was 7,285 (targeting 6,381 unique
proteins). Samples for which any SomaLogic normalization scale factor was outside [0.4-2.5]
(n=247) and those detected as 0s using an approach based on PCA and the local outlier
factor statistic (https://privefl.github.io/blog/detecting-outlier-samples-in-pca/) were
excluded (n=0 for the method excluding outliers and n=5 for capping outliers). Plate

correction was further applied through a residual approach: for each SOMAmer, its
measurements were corrected for plate effect estimated in linear mixed effect models
adjusted for center, age, sex, BMI, smoking status, and incidence of multiple cancer types,
CVD, T2D, neurodegenerative diseases and death, to preserve possible biological variation
due to these factors. Finally, only the samples belonging to the EPIC4ND case-cohort were
retained (n=6,543 for both outlier handling methods).

Measurements of each SOMAmer were $\log_{10}$-transformed and further centered and scaled
so that their mean was 0 and their standard deviation was 1 in the subcohort.
Measurements deviating more than 5 SD from the mean of the normalized $\log_{10}$-
transformed data were either excluded or 'capped' i.e., set to the value of 5 SD from the
normalized $\log_{10}$-transformed mean. The first approach is based on the assumption that
outliers represent technical or biological variation unrelated to PD (e.g., outliers due to
blood type or sex or genetic variation not associated with PD) obscuring any association
signal nearer to the mean. However, as we also acknowledge that outliers may represent
strong PD biomarker signals, in the discovery phase, we equally ran all statistical analyses by
capping these outliers. For all statistically significant findings, $\log_{10}$-transformed values were
visually inspected (**Supplementary Figure 10**) to verify the appropriateness of the data
transformation and the cutoff for the outlier removal. In the subsequent text and main
tables, protein names based on results using capped data are labeled with an 'cap'.

Statistical analysis in EPIC4PD

The final effective EPIC4PD case-cohort included 4,538 EPIC4PD participants including 574
incident PD cases with 7,285 aptamers (corresponding to 6,381 proteins) available for
statistical analysis. We used Cox proportional hazard regression analyses to examine the
association of 7,285 aptamers with instantaneous risk of PD using age as time scale and
Prentice weights to take into account the case-cohort setting [53]. Our basic model was
stratified (i.e., separate baseline hazard functions estimated) for 5-year age intervals, sex,
and center. Cox proportional hazards regression was performed using three distinct time
windows relative to disease onset: the full follow-up time period (2-28 years from baseline
to diagnosis/censoring), as well as two shorter periods therein: 2-10 and 10-20 years.
Furthermore, we performed sex-specific analyses after stratification for men and women

using the full follow-up time period. Differences between sex-stratified effect estimates

were tested by interaction analyses as previously described[54,55].

Proteomic results were defined as significant at a FDR of 0.05. Furthermore, we defined

"suggestively significant biomarker signals" as those findings that did not withstand FDR

control in the proteomic analyses but had a p-value $<10^{-3}$ and demonstrated consistency

across all EPIC4PD analyses — specifically, at least two nominally significant (p<0.05) results

and all effect estimates pointing in the same direction of effect.

In sensitivity analyses for all FDR-significant results, we tested a 'full' adjustment model

including the baseline covariates school education (no education/primary school vs higher

education), smoking status (dummy-coded as 'never', 'former', 'current'), body mass index

(BMI; weight/height^2 [kg/m^2]), and physical activity (dummy-coded as 'inactive', 'moderately

inactive', 'moderately active/active'). Furthermore, for FDR-significant results derived from

analyses stratified for women, we adjusted for postmenopausal status (dummy-coded as

premenopausal, postmenopausal, perimenopausal, and surgical postmenopausal status) and

use of hormones for menopause (yes/no).

HR trajectories were computed using 5-year sliding windows in one-year steps. For the

analyses of the sliding windows close to age at diagnosis, the 23 participants diagnosed with

PD within two years of baseline and previously excluded from the main analyses were re-

included. Due to more limited numbers of cases toward the end of follow-up, the final

window covered diagnoses occurring 16 to 25 years after baseline. Curves were fitted using

the geom_smooth() function from the ggplot2 package in R.

Independent replication of predictive biomarkers in prospective cohorts

Replication analyses of FDR-significant predictive biomarkers were performed on 64,856

individuals (1,034 incident PD cases) across three different prospective cohorts (AGES[56],

ARIC[57], UKB[58]) based on Olink (UKB) and SomaScan (AGES, ARIC) data, respectively.

The first replication cohort, the Age Gene/Environment Susceptibility-Reykjavik (AGES-

Reykjavik) Study[59], is a population-based study of adults aged 65 years and older in Iceland,

designed to investigate genetic susceptibility and gene-environment interactions related to

age-associated diseases. Between 2002 and 2006, 5,764 participants, which were survivors

of the original Reykjavik Study, underwent comprehensive interviews, examinations, and

measurements. The study was approved by the Icelandic National Bioethics Committee

(VSN: 00–063), the Icelandic Data Protection Authority, and the NIA IRB; all participants

provided written informed consent. Proteomic profiling of baseline serum samples from the

AGES cohort has been described previously[60]. After quality control and exclusion of

prevalent PD cases, 5,308 participants had available proteomic data, further reduced to

5,090 when applying a 2-year washout period. Over the follow-up, 121 participants

developed incident PD. In AGES, aptamer levels were log10-transformed. Further details on

recruitment can be found in ref.[61], and prevalent PD case ascertainment in ref.[62]. Medical

and mortality records (ICD10: G20) up to 2019-03-19 were reviewed to ascertain incident PD

cases.

The 2nd replication cohort, ARIC[57], is an ongoing community-based cohort study, for which

participants were enrolled from four communities across the United States: Washington

County, MD; Forsyth County, NC; northwestern suburbs of Minneapolis, MN; and Jackson,

MS. The ARIC participants who had SomaScan 5K data available (4,953 aptamers passing

quality control) comprised 11,205 middle-aged participants at baseline of whom 164

developed incident PD applying a washout period of two years and had SomaScan data in

EDTA plasma samples available. For details on the cohort recruitment and ascertainment of

incident PD cases therein please see ref.[63] and the **Supplementary Material**. All participants

provided appropriate written consent.

The 3rd replication cohort, UKB[58], is a general population cohort study, which performed

proteomic profiling of blood plasma samples using the Olink Explore 3072 platform (n=2,923

proteins, cohort size analyzed in this study: n=48,561 UKB participants including 749 incident

PD cases). The plasma samples were collected in volunteers aged 40 to 69 years at their first

attendance to a UKB assessment center in 22 centres across the United Kingdom between

2006 to 2010. Follow-up began from the date of attendance to an assessment center (field

53) to the first recorded date of diagnosis (ICD-10 code G20) in the patient-linked hospital

episode statistics (fields 41270 and 41280) or death registration (fields 40001 and 40002),

whichever occurred first, with the last recorded date in January 2023. Due to small case

numbers in other strata, the analysis was restricted to white participants (field 21000).

Participants with missing proteomics data were removed prior to each model.

Due to smaller sample sizes in the restricted time windows, we did not analyze top EPIC4PD

biomarkers in AGES for the time-window of 2-10 years of follow-up (n cases=26) and for

ARIC for the time window of 10-20 years of follow-up (n cases=32). Consistent with the

EPIC4PD analyses, outliers in AGES and UKB were either capped at or excluded beyond 5 SD,

depending on the approach used for the specific biomarker to be replicated. In AGES and

UKB, outliers were either capped at or excluded beyond 5 SD, in line with EPIC4PD analyses.

Outliers in ARIC were capped at 5 SD. Cox proportional hazards regression models were

harmonized for AGES, ARIC and UKB with EPIC4PD: The Cox model was based on age as time

scale and stratified (separate baseline hazard functions estimated) for age in 5-year

categories, race (in ARIC), and sex. Significance for the replication arm was defined at

$\alpha=0.05$. As sensitivity analysis, we also performed the same analyses only on white

participants in ARIC (excluding 2,625 black participants). However, as results did not change

substantially, we only report results on all participants in this study.

Indirect replication and characterization of preclinical EPIC4PD biomarkers for clinical

phenotypes in GNPC

The FDR-significant preclinical biomarkers identified in EPIC4PD across the three follow-up

periods and after stratification for sex were assessed for an association with prevalent PD

leveraging a large case-control dataset of the GNPC (335 prevalent cases and 2,257 controls

from 3 contributors) by re-analyzing the data described in the companion manuscript of

Imam et al.[14] All individuals included had undergone SomaScan 7K proteomic profiling as

part of the GNPC initiative. For this analysis, we restricted inclusion to datasets that

contained both PD cases and controls. Control participants were those without a

documented clinical diagnosis of mild cognitive impairment, dementia, AD, frontotemporal

dementia, PD, or ALS. To minimize bias from population stratification and ensure

comparability with EPIC4PD, we only included white participants in datasets where the

variable "race" was available. If no race information was provided, all participants were

included. The protein data was log10-transformed and standardized and values above or

below five standard deviations from the mean were excluded. Then, the case-control

datasets were residualized using the removeBatchEffect function from the R package limma

to regress out the effects of age, sex, and contributor, thereby controlling for confounding

sources of variation in the high-dimensional data. A principal component (PC) analysis was

then performed on the residuals; based on the scree plot, the first two PCs were retained as

additional covariates. Finally, logistic regression analyses were conducted on the original

data, adjusting for age, sex, dummy-coded contributor, and the first two PCs (all results from

the re-analyses with p<0.05 can be found in **Supplementary Table 22**). Analogous to the

EPIC4PD analyses, preclinical biomarkers that were FDR-significant in one sex stratum were

analyzed for the GNPC data within that specific sex group.

Concordance of effect estimates in EPIC4PD and GNPC (for all 47 significant preclinical

biomarkers as well as for nominally significant biomarkers shared by both studies) we

applied a one-sided binomial exact test. All analyses were performed in R.

We analyzed serum proteomic data from the Tracking Parkinson's disease cohort using the

SomaScan v4.1 (7K) assay (SomaLogic). Our cohort included 794 PD patients with serum

samples and clinical progression data across the three study visits (at 0 months, 18 months,

36 months). To correct for batch effects introduced by collection site, we used the ComBat

function from the sva R package (v3.50.0), with site as the batch variable, followed by $\log_{10}$-

transformation. For association analyses with PD progression, we investigated associations

between protein levels and two clinical outcomes: the Unified Parkinson's Disease Rating

Scale Part III (UPDRS-III) as a measure of motor function, and the Montreal Cognitive

Assessment (MoCA) as a measure of cognitive function.

Cross-sectional associations were assessed using generalized linear models, adjusting for

age, sex, and Levodopa Equivalent Daily Dose (LEDD) as a measure of treatment exposure.

For longitudinal analyses across up to to three visits per participant, we applied linear mixed-

effects models using the lmer() function from the lme4 R package. These models included a

random intercept for participant ID to account for repeated measures, and fixed effects for

protein level ($\log_{10}$ RFU), visit, age, sex, and LEDD. In additional sensitivity analyses, we

included BMI and disease duration (time since diagnosis at baseline) as covariates. Protein

associations were evaluated separately for each outcome, and p-values were adjusted for

multiple testing using an FDR=0.05.

Comparison to previous studies

We compiled a list of 291 unique candidate biomarkers previously linked to PD based on

findings from studies that employed a range of different methodologies (several proteins

were nominated more than once): These included i) 38 proteins from the only previous

proteomic study on future PD performed on 2,920 proteins based on Olink measurements in

the UKB[10], ii) 10 of ~2,700 analyzed blood plasma proteins (7 derived from Olink and 3 from

SomaScan studies) recently proposed as potential predictive biomarkers for PD by a

comprehensive MR study[16], iii) 18 proteins nominated by a recent MR and colocalization

study[64], iv) 109 proteins corresponding to nominated functional candidate and/or the

nearest genes located in 78 genetic risk loci described in the most recent Caucasian genome-

wide association study for PD [17], and v) 127 preselected neurodegenerative disease

candidate biomarkers included in the 'CNS NULISA panel' (Alamar, Inc.). Proteins available in

our SomaScan 7K data from this list (n=180) were tested for association in EPIC4PD. Results

were controlled applying an FDR=0.05 across all 180 candidate proteins available for testing

in our SomaScan 7K data.

Cross-disease comparisons

For cross-disease comparisons between PD and AD as well as between PD and ALS, we

performed Cox proportional hazard regression analyses for all FDR-significant PD proteins in

EPIC4AD (1,926 EPIC participants including 652 incident AD cases during a follow-up of 2-29

years) and EPIC4ALS (4,715 EPIC participants including 187 incident ALS cases during a

follow-up of 2-30 years) using Prentice-weighted Cox proportional hazard regression analysis

stratified for 5-year age groups, sex, and center, as described above. Results were controlled

at an FDR=0.05 in the context of all tested top biomarkers per disease. Furthermore, we

assessed whether significant associations in incident AD and ALS were enriched among all

proteins that were at least nominally significant in PD (based on the full follow-up period,

outliers excluded), using a one-sided Fisher's exact test. To assess whether overlapping

nominally significant proteins exhibited concordant effect directions more often than

expected by chance, we performed a one-sided binomial test. Furthermore, we assessed the

correlation of effect sizes between traits by calculating Pearson's correlation coefficients

based on the beta estimates. To prevent bias in the correlation due to the discontinuity

introduced by limiting the analysis to nominally significant results, we aligned effect

directions by mirroring the beta coefficients: for proteins with negative betas in PD, we

multiplied all corresponding betas in EPIC4PD and GNPC by −1 (generating 'mirrowed beta

values').

Brain expression data and protein abundance of top biomarkers

Gene expression and protein abundance of top PD biomarkers across tissues and in the brain

were assessed based on RNA-Seq and immunohistochemisty (IHC) data obtained from the

Human Protein Atlas (HPA v24.0, based on Ensembl version 109, accessed May 6th, 2025 at

https://www.proteinatlas.org/about/download) [65]. FDR-significant proteins were probed for

tissue expression using bulk RNA sequencing (RNA-Seq) data across 50 human tissues

available as gene-level 'Consensus RNA data' (rna_tissue_consensus.tsv.zip). Furthermore,

brain expression was assessed based on gene-level bulk RNA-Seq data across 13 brain

regions based on samples from the Human Brain Tissue Bank (Semmelweis University,

Budapest; rna_brain_region_hpa.tsv.zip) and based on single nucleus RNA-Seq (snRNA-Seq)

data across 11 brain regions (rna_single_nuclei_cluster_type.tsv.zip). Protein measurements

for the FDR-significant biomarkers across 45 human tissues were obtained from HPA based

on IHC using tissue microarrays (normal_ihc_data.tsv.zip). To visualize expression patterns of

the top biomarkers, heatmaps were generated using hierarchical clustering, with expression

values scaled per gene highlighting tissue-specific variation.

Gene set, cell type enrichment and network analyses

Gene set enrichment analyses were performed based on the GO classification system using

the PANTHER resource (Protein ANalysis THrough Evolutionary Relationships; version 19.0;

released 2024-06-20; https://geneontology.org/). A list of all unique proteins that showed a

suggestive signal in EPIC4PD and was uniquely mapped to a gene by PANTHER (n=154) was

tested for enrichment for 'biological process', 'molecular function', and 'cellular component'

GO categories as well as 'Reactome pathways'. The statistical overrepresentation test was

conducted using Fisher's exact test with the reference list set to all analyzed SomaScan 7K

proteins uniquely mapped by PANTHER (n=6,332). To avoid spurious associations, only GO

categories with at least ten proteins present in the background list were considered.

Cell enrichment analyses were performed using the the Expression Weighted Cell Type

Enrichment (EWCE) method to predict the likely primary disease-associated cells based on

our prioritised proteins[66]. This approach generates a probability distribution of gene

expression for specific cell types by comparing a target gene list to a background gene set.

We applied EWCE to our protein lists and to either single-cell mouse brain expression data[67]

or RNA expression data from 23 selected cell types sourced from the Human Protein Atlas

(dataset: rna_single_cell_type.tsv.zip)[65]. Each analysis was controlled at an FDR=0.05.

CorrelationAnalyzeR was used to investigate the coexpression of all FDR-significant

preclinical biomarkers. Coexpression with *SNCA* was specifically examined in 12,712 normal

GEO samples from immune cells and 3,198 normal GEO samples from brain. Permutation t

tests against random gene lists of the same size were used to determine correlation
significance with SNCA.

Protein-protein interaction network analysis

Furthermore, protein-protein interaction (PPI) networks were built using the STRING
database (v12.0, accessed May 6th, 2025 at https://string-db.org)[68] based on all FDR-
significant EPIC4PD biomarkers and plot using igraph (v2.1.4). Interactions with a minimum
interaction score of 0.4 were based on the following sources: 'textmining', 'experiments',
'databases', 'co-expression", "neighborhood', 'gene fusion', and 'co-occurrence'.
Furthermore, to examine the list of suggestive preclinical proteins in relation to known PD
genes, we utilized 109 proteins described in the most recent genome-wide association study
for PD (see above)[17]. P values were calculated based on the observed interactions compared
to 10,000 random permutations. Nodes not connected to the largest component were
removed from the PPI network Figure 3.

Drug Repurposing

We leveraged the Open Targets platform[19] to explore druggability and drug-repurposing
potential for all FDR-significant, putative preclinical PD biomarkers. Open Targets integrates
multiple data sources to systematically link genes and proteins with drug molecules and
disease associations. We queried the database focusing on small-molecule evidence,
excluding other therapeutic modalities such as biologics or gene therapies. Specifically,
approximately 17,000 small-molecule drugs and 21,087 protein targets were screened for
evidence of interaction with the 47 FDR-significant biomarkers. Evidence of druggability was
defined by reported direct binding or predicted high-quality pharmacological modulation
supported by curated experimental, 3D protein structure or clinical data within the Open
Targets resource.

Prediction

To assess the proteins' performance in risk stratification for PD, we performed variable
selection in a Cox proportional hazards model using the Least Absolute Shrinkage and
Selection Operator (LASSO) for variable selection and regularization. LASSO was
implemented via the R package glmnet, using function cv.glmnet(family="cox",
type.measure="C"). As the univariate Cox models had suggested substantial differences

between sex strata, we developed the PPRS for each sex stratum separately. and center by

stratified Cox models, using the StratifySurv() function[69]. For robust results we employed

stability selection[70]. Specifically, individually for each stratum, we fitted LASSO penalized Cox

models to 100 resampled datasets, each comprising a 63.2% subsample of individuals.

Complete follow-up in each resampling dataset was considered. Missing protein abundance

was imputed using k-nearest neighbor imputation (package: impute, function impute.knn()).

Imputation was performed within each training subset to avoid data leakage. In each

subsample, the optimal amount of regularization (lambda) was inferred through 5-fold cross-

validation using the C-index as performance criterion. The model coefficients (weights) from

all 100 runs were retained for downstream analysis. We computed the inclusion frequency

and average coefficient for each protein across the 100 permutations. To reduce the risk of

overfitting, we evaluated sparse protein subsets, using the 5, 10, 20, 50 and 100 most

frequently selected proteins from the initial LASSO selection (**Supplementary Table 20**). For

each EPIC4PD participant, a multivariate risk score (PPRS) was computed as the sum of the

protein values multiplied by the respective average weights across permutations. Cox

proportional hazards regression models were then fitted for each sex stratum with the sex-

specific risk score as the predictor, stratified by center and adjusted for age at examination.

In order to quantify the incremental benefit of the proteins, the model was also calculated

without the risk score as a predictor. Model performance was quantified using the

concordance index (C-index) obtained from summary(model)$concordance. Accuracy was

determined in AGES as an external validation cohort (n=5,090, including 121 incident PD

cases). For comparison purposes, PPRS were also explored without stratifying by sex. In this

case, the basic model contained age at examination and sex.

References

1. Poewe, W. *et al.* Parkinson disease. *Nat Rev Dis Primers* **3**, 1–21 (2017).

2. Ray Dorsey, E. *et al.* Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol* **17**, 939–953 (2018).

3. Ishihara, L. S., Cheesbrough, A., Brayne, C. & Schrag, A. Estimated life expectancy of Parkinson's patients compared with the UK population. *J Neurol Neurosurg Psychiatry* **78**, 1304–1309 (2007).

4. Postuma, R. B. & Berg, D. Advances in markers of prodromal Parkinson disease. *Nature Reviews Neurology* vol. 12 622–634 Preprint at https://doi.org/10.1038/nrneurol.2016.152 (2016).

5. Carrasco-Zanini, J. *et al.* Proteomic signatures improve risk prediction for common and rare diseases. *Nat Med* **30**, 2489–2498 (2024).

6. Deng, Y.-T. *et al.* Atlas of the plasma proteome in health and disease in 53,026 adults. *Cell* (2024) doi:10.1016/j.cell.2024.10.045.

7. Helgason, H. *et al.* Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. *JAMA* **330**, 725–735 (2023).

8. Zetterberg, H. Clinically relevant factors for blood-based Alzheimer biomarker interpretation. *Alzheimer's & Dementia* **19**, (2023).

9. Gail, M. H. *et al.* Design choices for observational studies of the effect of exposure on disease incidence. *BMJ Open* **9**, (2019).

10. Gan, Y.-H. *et al.* Large-scale proteomic analyses of incident Parkinson's disease reveal new pathophysiological insights and potential biomarkers. *Nat Aging* **5**, 642–657 (2025).

11. Lill, C. M. *et al.* EPIC4ND: European Prospective Investigation into Cancer and Nutrition follow-up for neurodegenerative diseases. Preprint at https://doi.org/10.1101/2025.01.29.25321340 (2025).

12. Riboli, E. & Kaaks, R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. *Int J Epidemiol* **26**, 6S – 14 (1997).

13. Riboli, E. *et al.* European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. *Public Health Nutr* **5**, 1113–1124 (2002).

14. Imam, F. *et al.* The Global Neurodegeneration Proteomics Consortium: Biomarker and Drug Target Discovery Across ~35,000 Biosamples Analyses for AD, PD, ALS, FTD, and Aging. [#NMED-A141443]. Niklas Mattsson-Carlgren vol. 15.

15. Doostparast Torshizi, A. *et al.* Proteogenomic network analysis reveals dysregulated mechanisms and potential mediators in Parkinson's disease. *Nat Commun* **15**, 6430 (2024).

16. Belbasis, L., Morris, S., van Duijn, C., Bennett, D. & Walters, R. Mendelian randomization identifies proteins involved in neurodegenerative diseases. *Brain* awaf018 (2025) doi:10.1093/brain/awaf018.

17. Nalls, M. A. *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* **18**, 1091–1102 (2019).

18. Doostparast Torshizi, A. *et al.* Proteogenomic network analysis reveals dysregulated mechanisms and potential mediators in Parkinson's disease. *Nat Commun* **15**, 6430 (2024).

19. Buniello, A. *et al.* Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. *Nucleic Acids Res* **53**, D1467–D1475 (2025).

20. Lundberg, M., Eriksson, A., Tran, B., Assarsson, E. & Fredriksson, S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Res* **39**, (2011).

21. Pietzner, M. *et al.* Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. *Nat Commun* **12**, (2021).

22. Eldjarn, G. H. *et al.* Large-scale plasma proteomics comparisons through genetics and disease associations. *Nature* **622**, 348–358 (2023).

23. Eldjarn, G. H. *et al.* Correction to: Large-scale plasma proteomics comparisons through genetics and disease associations (Nature, (2023), 622, 7982, (348-358), 10.1038/s41586-023-06563-x). *Nature* vol. 630 E3 Preprint at https://doi.org/10.1038/s41586-024-07549-z (2024).

24. Rooney, M. R. *et al.* Correlations Within and Between Highly Multiplexed Proteomic Assays of Human Plasma. *Clin Chem* **71**, 677–687 (2025).

25. Wang, B. *et al.* Comparative studies of 2168 plasma proteins measured by two affinity-based platforms in 4000 Chinese adults. *Nat Commun* **16**, 1869 (2025).

26.   Lill, C. M. *et al.* (Dys)regulation of the Immune System in Parkinson's Disease: Methodologies, Techniques, and Key Findings from Human Studies. *Aging Dis* (2025) doi:10.14336/AD.2024.1163.

27.   Tansey, M. G. *et al.* Inflammation and immune dysfunction in Parkinson disease. *Nat Rev Immunol* **22**, 657–673 (2022).

28.   Kedmi, M., Bar-Shira, A., Gurevich, T., Giladi, N. & Orr-Utreger, A. Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. *Mol Neurodegener* **6**, 66 (2011).

29.   Tatenhorst, L. *et al.* Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease. *Sci Rep* **14**, 5005 (2024).

30.   Fan, Y. *et al.* Increased plasma lipocalin-2 levels are associated with nonmotor symptoms and neuroimaging features in patients with Parkinson's disease. *J Neurosci Res* **102**, e25303 (2024).

31.   Elango, R. *et al.* Potential Biomarkers for Parkinson Disease from Functional Enrichment and Bioinformatic Analysis of Global Gene Expression Patterns of Blood and Substantia Nigra Tissues. *Bioinform Biol Insights* **17**, 11779322231166214 (2023).

32.   Hepp, D. H. *et al.* Inflammatory Blood Biomarkers Are Associated with Long-Term Clinical Disease Severity in Parkinson's Disease. *Int J Mol Sci* **24**, (2023).

33.   Yao, L. *et al.* Bioinformatic Analysis of Genetic Factors from Human Blood Samples and Postmortem Brains in Parkinson's Disease. *Oxid Med Cell Longev* **2022**, 9235358 (2022).

34.   Irmady, K. *et al.* Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson's disease. *Nat Commun* **14**, 3956 (2023).

35.   Miki, Y. *et al.* Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson's disease. *Neurobiol Aging* **63**, 33–43 (2018).

36.   Santiago, J. A., Littlefield, A. M. & Potashkin, J. A. Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. *Sci Rep* **6**, 34579 (2016).

37.   Kim, B.-W. *et al.* Pathogenic Upregulation of Glial Lipocalin-2 in the Parkinsonian Dopaminergic System. *J Neurosci* **36**, 5608–22 (2016).

38.   Hastings, N. *et al.* Connexin 43 is downregulated in advanced Parkinson's disease in multiple brain regions which correlates with symptoms. *Sci Rep* **15**, 10250 (2025).

39.   Lorenzl, S., Albers, D. S., Narr, S., Chirichigno, J. & Beal, M. F. Expression of MMP-2, MMP-9, and MMP-1 and their endogenous counterregulators TIMP-1 and TIMP-2 in postmortem brain tissue of Parkinson's disease. *Exp Neurol* **178**, 13–20 (2002).

40.   Morris, H. R., Spillantini, M. G., Sue, C. M. & Williams-Gray, C. H. The pathogenesis of Parkinson's disease. *Lancet* **403**, 293–304 (2024).

41.   Heinzel, S. *et al.* Update of the MDS research criteria for prodromal Parkinson's disease. *Movement Disorders* vol. 34 1464–1470 Preprint at https://doi.org/10.1002/mds.27802 (2019).

42.   Bestwick, J. P. *et al.* Improving estimation of Parkinson's disease risk—the enhanced PREDICT-PD algorithm. *NPJ Parkinsons Dis* **7**, (2021).

43.   Marini, K. *et al.* Comparison of different risk scores for Parkinson disease in a population-based 10-year study. *Eur J Neurol* **30**, 3347–3352 (2023).

44.   Irmady, K. *et al.* Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson's disease. *Nat Commun* **14**, 3956 (2023).

45.   Santiago, J. A., Littlefield, A. M. & Potashkin, J. A. Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. *Sci Rep* **6**, 34579 (2016).

46.   Kedmi, M., Bar-Shira, A., Gurevich, T., Giladi, N. & Orr-Utreger, A. Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. *Mol Neurodegener* **6**, 66 (2011).

47.   Tatenhorst, L. *et al.* Glypican-4 serum levels are associated with cognitive dysfunction and vascular risk factors in Parkinson's disease. *Sci Rep* **14**, 5005 (2024).

48.   Miki, Y. *et al.* Alteration of autophagy-related proteins in peripheral blood mononuclear cells of patients with Parkinson's disease. *Neurobiol Aging* **63**, 33–43 (2018).

49.   Gallo, V. *et al.* Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. *Neurodegener Dis* **15**, 331–338 (2015).

50.   Consortium, T. I. Design and cohort description of the InterAct Project: an examination of the interaction of genetic and lifestyle factors on the incidence of type 2 diabetes in the EPIC Study. *Diabetologia* **54**, 2272–2282 (2011).

1116   51.   Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *PLoS One* **5**, (2010).

1117   52.   Candia, J., Daya, G. N., Tanaka, T., Ferrucci, L. & Walker, K. A. Assessment of variability in the plasma 7k SomaScan
1118   proteomics assay. *Sci Rep* **12**, (2022).

1119   53.   PRENTICE, R. L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. *Biometrika* **73**,
1120   1–11 (1986).

1121   54.   Altman, D. G. & Bland, J. M. Interaction revisited: the difference between two estimates. *BMJ* **326**, 219 (2003).

1122   55.   Lill, C. M. *et al.* Impact of Parkinson's disease risk loci on age at onset. *Movement Disorders* **30**, 847–850 (2015).

1123   56.   Harris, T. B. *et al.* Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary Applied Phenomics. *Am
1124   J Epidemiol* **165**, 1076–1087 (2007).

1125   57.   Wright, J. D. *et al.* The ARIC (Atherosclerosis Risk In Communities) Study. *J Am Coll Cardiol* **77**, 2939–2959 (2021).

1126   58.   Sudlow, C. *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex
1127   Diseases of Middle and Old Age. *PLoS Med* **12**, e1001779- (2015).

1128   59.   Harris, T. B. *et al.* Age, Gene/Environment Susceptibility-Reykjavik Study: multidisciplinary applied phenomics. *Am J
1129   Epidemiol* **165**, 1076–87 (2007).

1130   60.   Bankier, S. *et al.* Circulating causal protein networks linked to future risk of myocardial infarction. *medRxiv* (2025)
1131   doi:10.1101/2025.02.07.25321789.

1132   61.   Harris, T. B. *et al.* Age, Gene/Environment Susceptibility-Reykjavik Study: Multidisciplinary Applied Phenomics. *Am
1133   J Epidemiol* **165**, 1076–1087 (2007).

1134   62.   Scher, A. I. *et al.* Midlife migraine and late-life parkinsonism: AGES-Reykjavik study. *Neurology* **83**, 1246–52 (2014).

1135   63.   Huang, X. *et al.* Statins, plasma cholesterol, and risk of Parkinson's disease: a prospective study. *Mov Disord* **30**,
1136   552–9 (2015).

1137   64.   Doostparast Torshizi, A. *et al.* Proteogenomic network analysis reveals dysregulated mechanisms and potential
1138   mediators in Parkinson's disease. *Nat Commun* **15**, (2024).

1139   65.   Karlsson, M. *et al.* A single–cell type transcriptomics map of human tissues. *Sci Adv* **7**, eabh2169 (2025).

1140   66.   Skene, N. G. & Grant, S. G. N. Identification of Vulnerable Cell Types in Major Brain Disorders Using Single Cell
1141   Transcriptomes and Expression Weighted Cell Type Enrichment. *Front Neurosci* **Volume 10-2016**, (2016).

1142   67.   Zeisel, A. *et al.* Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science (1979)*
1143   **347**, 1138–1142 (2015).

1144   68.   Szklarczyk, D. *et al.* The STRING database in 2023: protein–protein association networks and functional enrichment
1145   analyses for any sequenced genome of interest. *Nucleic Acids Res* **51**, D638–D646 (2023).

1146   69.   Simon, N., Friedman, J., Hastie, T. & Tibshirani, R. Regularization Paths for Cox's Proportional Hazards Model via
1147   Coordinate Descent. *J Stat Softw* **39**, (2011).

1148   70.   Meinshausen, N. & Bühlmann, P. Stability Selection. *J R Stat Soc Series B Stat Methodol* **72**, 417–473 (2010).

1149